Non Hodgkin Lymphoma

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Pre-malignant States to Hematologic Malignancies in Firefighters

TmCD19-IL18 in CD19+ Cancers

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Administration of Donor T Cells With the Caspase-9 Suicide Gene

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

Familial Investigations of Childhood Cancer Predisposition

Methionine PET/CT Studies In Patients With Cancer

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation